Sodium dichloroacetate

Drug Profile

Sodium dichloroacetate

Alternative Names: Ceresine; CPC-211

Latest Information Update: 13 Oct 2005

Price : $50

At a glance

  • Originator Michigan State University
  • Developer Questcor Pharmaceuticals
  • Class Acetates; Antineoplastics; Nootropics; Small molecules
  • Mechanism of Action Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Craniocerebral trauma; Lactic acidosis; Spinal cord injuries; Stroke

Most Recent Events

  • 13 Oct 2005 Discontinued - Clinical-Phase-Unknown for Lactic acidosis in USA (unspecified route)
  • 13 Oct 2005 Discontinued - Phase-I for Stroke in USA (IV)
  • 13 Oct 2005 Discontinued - Phase-I for Stroke in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top